Influenza A virus medicament screening yeast two-hybrid system and application thereof
An influenza A virus and yeast two-hybrid technology, applied in the field of genetic engineering, can solve the problems of screening specificity, low screening throughput, unclear mechanism of action of target drugs, etc., and achieve the effect of high specificity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0033] Example 1 of the present invention provides a target-specific influenza A virus drug screening yeast two-hybrid system using yeast two-hybrid plasmids pGADT7 and pGBKT7. The target-specific influenza A virus drug screening yeast two-hybrid system also includes The PB1 gene and PB2 gene of the international standard strain of influenza A virus A / PR8 / 34, the PB1 gene and pGBKT7 are recombined, and the PB2 gene and pGADT7 are recombined.
[0034] The DNA sequence complementary to the PB1 gene is shown in SEQ ID NO:1. In SEQ ID NO:1, the base sequence from position 25 to position 2298 corresponds to PB1 of the international standard strain of influenza A virus A / PR8 / 34 The protein coding region of the gene; the DNA sequence complementary to the base sequence of the PB2 gene is shown in SEQ ID NO: 2. In SEQ ID NO: 2, the base sequence from position 28 to position 2307 corresponds to Influenza A International The protein coding region of the PB2 gene of the standard strain A / PR8...
Embodiment 2
[0038] Example 2 of the present invention provides a target-specific influenza A virus drug screening yeast two-hybrid system, using yeast two-hybrid plasmids pGADT7 and pGBKT7, the target-specific influenza A virus drug screening yeast two-hybrid system also includes type A The PB1 gene and PA gene of the international standard influenza virus strain A / PR8 / 34, the PB1 gene and pGBKT7 are recombined, and the PA gene is recombined with pGADT7.
[0039] The DNA sequence complementary to the base sequence of the PB1 gene is shown in SEQ ID NO: 1; the DNA sequence complementary to the base sequence of the PA gene is shown in SEQ ID NO: 3, in SEQ ID NO: 3, The 25th to 2175th base sequence corresponds to the protein coding region of the PA gene of the international standard strain of influenza A virus A / PR8 / 34
[0040] The foreign gene sequence included in the target-specific influenza A virus drug screening yeast two-hybrid system is the PB1-pGBKT7 gene sequence of the international sta...
Embodiment 3
[0043] Example 3 of the present invention provides a target-specific influenza A virus drug screening yeast two-hybrid system. The target-specific influenza A virus drug screening yeast two-hybrid system includes the targets of Example 1 and Example 2. Site-specific influenza A virus drug screening yeast two-hybrid system.
[0044] Among them, the target-specific influenza A virus drug screening yeast two-hybrid system of Example 1 uses yeast two-hybrid plasmids pGADT7 and pGBKT7. The target-specific influenza A virus drug screening yeast two-hybrid system also includes influenza A The PB1 gene and PB2 gene of the virus international standard strain A / PR8 / 34, the PB1 gene and pGBKT7 are recombined, and the PB2 gene is recombined with pGADT7.
[0045] The target-specific influenza A virus drug screening yeast two-hybrid system of Example 2 uses yeast two-hybrid plasmids pGADT7 and pGBKT7. The target-specific influenza A virus drug screening yeast two-hybrid system also includes infl...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com